Integrating genomics and artificial intelligence to predict treatment responses in cancer patients is going to become a reality. A major collaborative research project “Artificial Intelligence and Genomics to Predict Cancer Treatment” has been awarded a $2.6 million CRC-P Grant (Cooperative Research Centre Projects) by Australian Government. The official announcement is made today by Assistant Minster for Science, Jobs and Innovation, Zed Seselja, and Federal Member for Brisbane, Trevor Evans on 25 Jul 2018.
BGI is the Next-Gen Sequencing partner of the Project, in collaboration with other world leading partners including Max Kelsen the leading partner specialised in artificial intelligence technology, QIMR Berghofer Medical Research Institute as the research partner, Queensland Health Metro North Hospital and Health Service as the clinical partner, and genomiQa as the bioinformatic analysis partner.
The Project will receive $2.6 million under the fifth round of the CRC-P Program, and has attracted $6.4 million of cash and in-kind contributions from industry partners. "This project will firmly establish the role of artificial intelligence and whole genome analysis in the future of precision medicine" said Nicholas Therkelsen-Terry CEO of Max Kelsen.
Colin Albert, CEO of genomiQa, a spin-out company of QIMR Berghofer Institute of Medical Research said the project would help to unlock the value of whole genome data for patients and clinicians. “This project will firmly establish the role of whole genome analysis and artificial intelligence to help predict the response of immunotherapy for the treatment of cancer.”
Mr Albert said genomiQa’s high-quality genomic pipeline was developed by founders Dr Nic Waddell and Dr. John Pearson.
Dr. Bicheng Yang, Director of BGI Australia said, “BGI is proud to provide sequencing support for this $9.1 million project, which will help establish whole genome sequencing as part of routine clinical practice, as BGI’s objective is to make sequencing more affordable and accessible to benefit the general public”. More in the News